Abstract:Key Points The matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that consist of more than 21 human MMPs and numerous homologues from other species. They can be divided into eight structural classes, three of which are membrane bound. The MMPs are synthesized as inactive zymogens and activated by proteinase cleavage. Their activity is regulated by endogenous inhibitors, including α2-macroglobulin; tissue inhibitors of metalloproteinases (TIMPs); small molecules with TIMP-like domains; and the membrane-bound inhibitor RECK (reversion-inducing cysteine-rich protein with kazal motifs). Direct evidence for a role of MMPs in tumour progression comes from xenograft experiments using cancer cells with decreased and increased expression levels of MMPs or TIMPs, and from carcinogenesis experiments with mice that either lack a specific Mmp or Timp-1 or have organ-specific Mmp or Timp-1 overexpression. MMPs are upregulated in almost every type of human cancer, and their expression is often associated with poor survival. Whereas some of the MMPs (for example, MMP-7) are expressed by the cancer cells, other MMPs (for example, MMP-2 and MMP-9) are synthesized by the tumour stromal cells, including fibroblasts, myofibroblasts, inflammatory cells and endothelial cells. MMPs can promote cancer progression by increasing cancer-cell growth, migration, invasion, metastasis and angiogenesis. MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases. Several synthetic MMP inhibitors are undergoing Phase III clinical trials. Although a few encouraging results have been reported, some trials were prematurely terminated due to either lack of benefits or major adverse effects. The clinical trials have so far focused on patients with advanced-stage disease. Based on animal experiments, we would expect, however, that clinical efficacy might be improved either by using MMP inhibitors in the treatment of early disease (in combination with conventional therapy), or as preoperative and postoperative treatment to prevent surgical-induced micrometastatic spread and recurrence of the disease.

Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease

Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal

Matrix metalloproteinases in kidney homeostasis and diseases: an update

Matrix metalloproteinases involvement in pathologic conditions

Matrix metalloproteases: variations on a theme

Matrix Metalloproteinases-7 and Kidney Fibrosis

The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics

Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair

Matrix metalloproteinases at a glance

Matrix Metalloproteinases in the Periodontium—Vital in Tissue Turnover and Unfortunate in Periodontitis

TNF-α and IL-1β–mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells

Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments

A glimpse of matrix metalloproteinases in diabetic nephropathy.

MMP-2 and 9 in Chronic Kidney Disease

New functions for the matrix metalloproteinases in cancer progression

Matrix Metalloproteinases and the Restenosis after Injury of Arterial Intima

Identification of matrix metalloproteinase-10 as a key mediator of podocyte injury and proteinuria

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

How matrix metalloproteinases regulate cell behavior.